Predictors of multidomain decline in health‐related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer

Abstract

Prostate SBRT has minimal long-term impact on multidomain decline, and the majority of more significant multidomain declines appear to be unrelated to treatment. This emphasizes the importance of focusing not only on the side effects of prostate cancer treatment but also on other comorbid illnesses that contribute to overall HRQOL. Cancer 2017;123:1635-1642. © 2017 American Cancer Society.

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

“…It is generally recognized that when assessing PROs, a change in these functions exceeding half of a standard deviation is a minimal important difference (29). Other investigators have suggested using other measures, such as 2 times the minimal important difference (33, 34). In this study, as per the National Cancer Institute (NCI)-approved protocol, we have reported on the results based on a change in PROs of greater than half of a standard deviation.…”

Symptoms predicting health-related quality of life in prostate cancer patients treated with localized radiation therapy

“…Most studies reported predictors of HRQOL years after radiation therapy for nonmetastatic prostate cancer. One of those studies revealed that baseline bowel issues and a depression diagnosis were independent predictors of HRQOL decline following stereotactic body radiation therapy (commonly known as CyberKnife) in prostate cancer men [ 16 ]. One study clearly described the trajectories of common symptoms reported by patients before, during, and after radiation therapy for prostate cancer [ 12 ].…”

“…These symptoms persist for 12–24 months following EBRT completion [ 12 , 13 ]. However, the reported short-term and long-term effects of these symptoms on HRQOL for this clinical population are inconsistent [ 3 , 11 , 13 – 16 ], most likely related to differences in the instruments and approaches used to measure HRQOL.…”

Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial

“…This article is protected by copyright. All rights reserved SBRT is convenient and cost-effective relative to conventional EBRT courses of 8-9 weeks (7,8), with a promising overall toxicity profile (9)(10)(11), that currently is being investigated in numerous randomized trials that have either already reported early results or finished accrual (12, 13).…”